Projects per year
Personal profile
Headline
PROFESSOR | Medicine, Hematology and Medical Oncology PROFESSOR | Urology
Biography
Specialty Hematology-Oncology Certifications Medical Oncology Clinical Focus Bladder Cancer Kidney Cancer Primary Pulmonary Hypertension Prostate Cancer Testicular Tumors Urologic Cancers Education Residency, Internal Medicine Beth Israel Deaconess Medical Center- Harvard Medical School Fellowship, Medical Oncology Memorial Sloan-Kettering Cancer Center Biography Dr. Galsky specializes in the care of patients with genitourinary malignancies (bladder, prostate, kidney, and testicular cancers). His research focuses on the development of novel treatments for these cancers and he has published extensively in this area. He serves as Director of Genitourinary Medical Oncology at the Tisch Cancer Institute. Awards 2003 - American Society of Clinical Oncology Merit Award 1998 - Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy) 1998 - Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology) 1997 - Alpha Omega Alpha Honor Society
Fingerprint
Dive into the research topics where Matthew Galsky is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
-
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
Bhardwaj, N., Bhardwaj, N., Galsky, M., Zhu, J. J., Galsky, M. & Zhu, J.
1/04/20 → 31/03/23
Project: Research
-
Cancer Research Institute Grants
Subudhi, S. S., Graff, J. J., Weintzel, K. K., Autio, K. K., Fong, L. L. & Galsky, M.
1/01/18 → …
Project: Research
-
Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring
Martini, A., Yu, M., Raggi, D., Joshi, H., Fallara, G., Montorsi, F., Necchi, A. & Galsky, M. D., 1 Aug 2022, In: Cancer. 128, 15, p. 2892-2897 6 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis
Fallara, G., Belladelli, F., Robesti, D., Raggi, D., Nocera, L., Marandino, L., Galsky, M. D., Montorsi, F., Malavaud, B., Ploussard, G., Necchi, A. & Martini, A., Nov 2022, In: Critical Reviews in Oncology/Hematology. 179, 103801.Research output: Contribution to journal › Review article › peer-review
-
Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (Nature Medicine, (2022), 28, 4, (626-629), 10.1038/s41591-022-01681-x)
Marron, T. U., Galsky, M. D., Taouli, B., Fiel, M. I., Ward, S., Kim, E., Yankelevitz, D., Doroshow, D., Guttman-Yassky, E., Ungar, B., Mehandru, S., Golas, B. J., Labow, D., Sfakianos, J., Nair, S. S., Chakravarty, D., Buckstein, M., Song, X., Kenigsberg, E., Gnjatic, S., & 6 others, Aug 2022, In: Nature Medicine. 28, 8, p. 1723 1 p.Research output: Contribution to journal › Comment/debate
Open Access -
Biomarkers for therapy selection in metastatic urothelial cancer
Jun, T., Anker, J. & Galsky, M. D., 2022, In: Journal of Cancer Metastasis and Treatment. 8, 1.Research output: Contribution to journal › Review article › peer-review
Open Access1 Scopus citations -
Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
Nikolos, F., Hayashi, K., Hoi, X. P., Alonzo, M. E., Mo, Q., Kasabyan, A., Furuya, H., Trepel, J., Di Vizio, D., Guarnerio, J., Theodorescu, D., Rosser, C., Apolo, A., Galsky, M. & Chan, K. S., Dec 2022, In: Nature Communications. 13, 1, 1487.Research output: Contribution to journal › Article › peer-review
Open Access11 Scopus citations
Press/Media
-
CheckMate 274 follow up data boost nivolumab potential for high-risk bladder cancer
8/03/23
1 item of Media coverage
Press/Media
-
Dr. Galsky on the Rationale for the CheckMate-274 Trial in Urothelial Cancer
8/03/23
1 item of Media coverage
Press/Media
-
Extended Follow-Up Reaffirms Benefit of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma
7/03/23
1 item of Media coverage
Press/Media
-
Risk-Adapted Approach for Muscle-Invasive Bladder Cancer Requires Further Refinement
1/03/23
1 item of Media coverage
Press/Media
-
Adjuvant nivolumab as standard of care in resected bladder cancer
22/02/23
2 items of Media coverage
Press/Media